Premium
Efficacy and safety of bone marrow‐derived cell transplantation for spinal cord injury: a systematic review and meta‐analysis of clinical trials
Author(s) -
Li Xiao Chuan,
Zhong Cheng Fan,
Deng Gui Bin,
Liang Rong Wei,
Huang Chun Ming
Publication year - 2015
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12580
Subject(s) - medicine , spinal cord injury , transplantation , cochrane library , meta analysis , clinical trial , randomized controlled trial , adverse effect , medline , surgery , spinal cord , psychiatry , political science , law
Purpose Bone marrow‐derived cells ( BMDC s) for clinical transplantation were carried out many years in treating spinal cord injury ( SCI ) without a clear conclusion. This study aimed to evaluate the safety and efficacy of BMDC transplantation in treatment of SCI patients. Method Electronic databases, including P ub M ed, EMBASE , MEDLINE , and the C ochrane library, were searched to identify clinical therapeutic trials studying the application of BMDC transplantation in SCI . Results Overall the quality of the 24 studies was low, including one G rade I level of evidence, six Grade II levels, three Grade III levels, and 14 G rade IV levels. With a maximum of six‐yr follow‐up, the procedure‐related complications were minor and temporary, without serious adverse events (p = 0, n = 594). AIS improvement rate was analyzed in favor of BMDC s 6.13 (95% CI , 3.0–12.51; p < 0.001). In patient with complete ( AIS A) and chronic SCI , the application of cell transplantation numbers between n × (10 7 –10 8 ) seemed to be more beneficial (p < 0.05 for all groups). Conclusions Based on short‐medium terms following up, BMDC transplantation appears to be safe and valid in SCI patients, more effective in chronic and complete injury. Nonetheless, prospective, randomized trials in larger cohorts are still needed.